NZ754328A - Marker for acid sphingomyelinase disorders and uses thereof - Google Patents

Marker for acid sphingomyelinase disorders and uses thereof

Info

Publication number
NZ754328A
NZ754328A NZ754328A NZ75432814A NZ754328A NZ 754328 A NZ754328 A NZ 754328A NZ 754328 A NZ754328 A NZ 754328A NZ 75432814 A NZ75432814 A NZ 75432814A NZ 754328 A NZ754328 A NZ 754328A
Authority
NZ
New Zealand
Prior art keywords
rhasm
subject
lyso
level
spm
Prior art date
Application number
NZ754328A
Other languages
English (en)
Inventor
Wei-Lien Chuang
Gerald Cox
X Zhang
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority claimed from NZ715001A external-priority patent/NZ715001B2/en
Publication of NZ754328A publication Critical patent/NZ754328A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
NZ754328A 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof NZ754328A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832302P 2013-06-07 2013-06-07
NZ715001A NZ715001B2 (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Publications (1)

Publication Number Publication Date
NZ754328A true NZ754328A (en) 2021-12-24

Family

ID=51062988

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ754328A NZ754328A (en) 2013-06-07 2014-06-06 Marker for acid sphingomyelinase disorders and uses thereof

Country Status (29)

Country Link
US (4) US10022428B2 (cg-RX-API-DMAC7.html)
EP (2) EP3004896B1 (cg-RX-API-DMAC7.html)
JP (4) JP6457501B2 (cg-RX-API-DMAC7.html)
KR (3) KR102292298B1 (cg-RX-API-DMAC7.html)
CN (2) CN105474017A (cg-RX-API-DMAC7.html)
AU (5) AU2014274670B2 (cg-RX-API-DMAC7.html)
CA (1) CA2914751C (cg-RX-API-DMAC7.html)
CL (1) CL2015003563A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150638A (cg-RX-API-DMAC7.html)
DK (1) DK3004896T3 (cg-RX-API-DMAC7.html)
EA (1) EA035342B1 (cg-RX-API-DMAC7.html)
ES (1) ES2762608T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20192246T1 (cg-RX-API-DMAC7.html)
HU (1) HUE047863T2 (cg-RX-API-DMAC7.html)
IL (3) IL284102B2 (cg-RX-API-DMAC7.html)
LT (1) LT3004896T (cg-RX-API-DMAC7.html)
MA (1) MA38638B1 (cg-RX-API-DMAC7.html)
MX (1) MX370570B (cg-RX-API-DMAC7.html)
MY (1) MY185990A (cg-RX-API-DMAC7.html)
NZ (1) NZ754328A (cg-RX-API-DMAC7.html)
PH (1) PH12015502687A1 (cg-RX-API-DMAC7.html)
PL (1) PL3004896T3 (cg-RX-API-DMAC7.html)
PT (1) PT3004896T (cg-RX-API-DMAC7.html)
RS (1) RS59677B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201709925SA (cg-RX-API-DMAC7.html)
SI (1) SI3004896T1 (cg-RX-API-DMAC7.html)
UA (1) UA120591C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014197859A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508630B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2470199T3 (pl) * 2009-08-28 2019-11-29 Icahn School Med Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
EP3004896B1 (en) * 2013-06-07 2019-09-18 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (ja) * 2015-10-08 2021-12-22 国立大学法人千葉大学 ニーマン・ピック病ｃ型を予防または治療するための医薬組成物
ES2970423T3 (es) * 2017-08-24 2024-05-28 Genzyme Corp Esfingomielinasa ácida humana recombinante para su uso en el tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida
EP3692070A1 (en) 2017-10-02 2020-08-12 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
EP4562432A2 (en) * 2022-07-28 2025-06-04 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
JP2006214731A (ja) 2005-02-01 2006-08-17 Institute Of Physical & Chemical Research スフィンゴミエリンの検出方法
CN101356283A (zh) 2005-12-15 2009-01-28 纽约州立大学研究基金会 用于测量血浆和组织鞘磷脂和磷脂酰胆碱的酶促方法
AR059089A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
PL2470199T3 (pl) * 2009-08-28 2019-11-29 Icahn School Med Mount Sinai Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy
JP2013002933A (ja) 2011-06-16 2013-01-07 Hitachi Plant Technologies Ltd ３次元測位システム
CA2854668A1 (en) * 2011-11-15 2013-05-23 Centogene Ag Method for the diagnosis of niemann-pick disease
TR201906195T4 (tr) * 2013-05-14 2019-05-21 Centogene Ag Niemann pıck hastalığının teşhisi için metot.
EP3004896B1 (en) * 2013-06-07 2019-09-18 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof

Also Published As

Publication number Publication date
KR102434244B1 (ko) 2022-08-19
MX370570B (es) 2019-12-17
MY185990A (en) 2021-06-14
EA201592265A1 (ru) 2016-04-29
IL284102A (en) 2021-07-29
AU2023201062B2 (en) 2025-05-29
KR20210104177A (ko) 2021-08-24
CN105474017A (zh) 2016-04-06
AU2025220876A1 (en) 2025-09-11
EA035342B1 (ru) 2020-05-29
AU2014274670A1 (en) 2016-01-07
US20160120958A1 (en) 2016-05-05
SG10201709925SA (en) 2017-12-28
PH12015502687A1 (en) 2016-03-07
KR102228367B1 (ko) 2021-03-16
AU2018200977B2 (en) 2020-07-23
AU2023201062A1 (en) 2023-03-23
ES2762608T3 (es) 2020-05-25
WO2014197859A1 (en) 2014-12-11
PT3004896T (pt) 2019-12-23
ZA201508630B (en) 2020-01-29
KR20160018651A (ko) 2016-02-17
BR112015030099A2 (pt) 2017-07-25
JP2024038145A (ja) 2024-03-19
HK1217534A1 (en) 2017-01-13
CA2914751C (en) 2023-10-03
IL298675B1 (en) 2025-08-01
SI3004896T1 (sl) 2020-01-31
JP2019089767A (ja) 2019-06-13
JP7414750B2 (ja) 2024-01-16
AU2014274670B2 (en) 2017-11-09
HRP20192246T1 (hr) 2020-03-06
CA2914751A1 (en) 2014-12-11
CR20150638A (es) 2016-02-08
IL242964B (en) 2021-07-29
JP6835806B2 (ja) 2021-02-24
EP3004896B1 (en) 2019-09-18
US10022428B2 (en) 2018-07-17
JP2021075544A (ja) 2021-05-20
MA38638B1 (fr) 2018-03-30
MA38638A1 (fr) 2017-02-28
RS59677B1 (sr) 2020-01-31
NZ715001A (en) 2021-10-29
PL3004896T3 (pl) 2020-04-30
US11998592B2 (en) 2024-06-04
AU2020257114B2 (en) 2023-03-16
MX2015016844A (es) 2016-04-04
KR20210031541A (ko) 2021-03-19
US20240398907A1 (en) 2024-12-05
IL298675A (en) 2023-01-01
CN115128287A (zh) 2022-09-30
US20210162021A1 (en) 2021-06-03
IL298675B2 (en) 2025-12-01
JP6457501B2 (ja) 2019-01-23
JP2016526050A (ja) 2016-09-01
EP3584580A1 (en) 2019-12-25
UA120591C2 (uk) 2020-01-10
KR102292298B1 (ko) 2021-08-24
HUE047863T2 (hu) 2020-05-28
LT3004896T (lt) 2020-01-10
IL284102B2 (en) 2023-04-01
EP3004896A1 (en) 2016-04-13
CL2015003563A1 (es) 2016-08-05
US10888607B2 (en) 2021-01-12
SG11201509622WA (en) 2015-12-30
US20180289778A1 (en) 2018-10-11
AU2018200977A1 (en) 2018-03-01
DK3004896T3 (da) 2020-01-06
IL284102B (en) 2022-12-01
AU2020257114A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX376652B (es) Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer.
MX2021013880A (es) Polimeros enlazados al proton para administracion oral.
IN2015DN00376A (cg-RX-API-DMAC7.html)
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
IN2015DN00450A (cg-RX-API-DMAC7.html)
MY168791A (en) Carbamate compounds and of making and using same
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
HK1210699A1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
MX382077B (es) Polimeros de union a protones para administracion oral.
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
PH12015502655A1 (en) Method
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
JP2013520447A5 (cg-RX-API-DMAC7.html)
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2023 BY CPA GLOBAL

Effective date: 20220421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2024 BY CPA GLOBAL

Effective date: 20230420

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240425

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 JUN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250424